Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2024 Lymphoma Highlights
30 January 2025 | Virtual Webinar
Post-ASH 2024 Lymphoma Highlights
Featuring presentations & discussions on selected lymphoma abstracts from the 66th ASH Annual Meeting and Exposition
Thursday 30 January | 11:30 – 13:30 CST/ 17:30 – 19:30 GMT/ 18:30 – 20:30 CET
Chair: Wendy Osborne | Moderators: Tycel Phillips and Laurie Sehn
The Post-ASH 2024 Lymphoma Highlights was supported by AstraZeneca, Bristol Myers Suibb, Genentech and Galápagos. Supporters have no influence over the production of content.
Explore all presentations and discussions below:
Session 1: Novel treatment combination approaches
Tafasitamab plus lenalidomide and rituximab for R/R FL: results from a Phase III study (inMIND)
Laurie Sehn BC Cancer Agency, Vancouver, Canada
Final analysis of the safety and efficacy of venetoclax in combination with Pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma
Catherine Diefenbach Perlmutter Cancer Center at NYU Langone Health, New York City, NY, United States
MRD-driven time-limited therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab in patients with treatment-naïve MCL: Phase II trial outcomes with MRD and cfDNA analyses
David Bond The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of Pola-R-CHP on outcomes
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Panel discussion
Session 2: Latest in stem cell transplant & CAR T-cell therapies
Lack of benefit of auto-HCT in MCL patients in first CR with uMRD: initial report from the ECOG-ACRIN EA4151 Phase III randomized trial
Brad Kahl Siteman Cancer Center, St. Louis, MO, United States
Autologous and allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT Lymphoma Working Party
Evgenii Shumilov Münster University Hospital, Münster, Germany
Rapcabtagene autoleucel (YTB323) in patients with R/R DLBCL: Phase II trial clinical update
Peter Riedell University of Chicago Medicine, Chicago, IL, United States
Interim results from a Phase II pivotal study (DALY II USA) of tandem CD20-CD19-directed non-cryopreserved CAR T-cells - zamto-cel in patients with R/R DLBCL
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
Real-world outcomes of liso-cel as 2L therapy in pts with R/R LBCL: first results from the CIBMTR registry
María Silvina Odstrcil Bobillo University of Utah, Salt Lake City, UT, United States
Panel discussion
Session 3: Advances with bispecifics & CELMoDs
Glofitamab in combination with rituximab plus ifosfamide, carboplatin, and etoposide shows favorable efficacy and manageable safety in patients with R/R DLBCL, eligible for stem cell transplant or CAR T-cell therapy: results from a Phase Ib study
Catherine Diefenbach Perlmutter Cancer Center at NYU Langone Health, New York City, NY, United States
Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with R/R LBCL: three-year follow-up from a pivotal Phase II study
Michael Dickinson Peter MacCallum Cancer Centre, Melbourne, Australia
Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in R/R LBCL
Evgenii Shumilov Münster University Hospital, Münster, Germany
Real-world outcomes with bispecific T-cell engagers for R/R LBCL: a multi-center, retrospective cohort study
Taylor Brooks Cleveland Clinic, Cleveland, OH, United States
Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with R/R FL: two-year follow-up from arm 2 of the EPCORE NHL-2 trial
Anna Sureda Catalan Institute of Oncology, Barcelona, Spain
Longer follow-up of golcadomide, a CELMoD agent + rituximab, in patients with R/R DLBCL
Jean-Marie Michot Gustave Roussy Institute, Paris, France
Panel discussion
